CURE

ASCO Updates First-Line Treatment for Stage 4 EGFR Lung Cancer

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...
Fierce Pharma

Lilly's rare cancer drug Retevmo looks to broaden reach with adjuvant trial win

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...
ascopubs.org

The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from ...
WebMD

What Is HER2-Mutated Non-Small-Cell Lung Cancer?

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
ascopubs.org

Prevalence of EGFR mutations in non-small cell lung cancer in Hawaii: A multi-center epidemiology study.

Global trends of early onset cancers (15-49 years) 1990-2021 and projection to 2040. Incidence and survival trends in adolescents and young adults with carcinoma of unknown primary: Insights from the ...
The American Journal of Managed Care

FDA Approves Sunvozertinib in Non–Small Cell Lung Cancer

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...
Targeted Oncology

Precision Oncology and the New Era of Lung Cancer

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...
News Medical

Study maps HER2 mutations in lung cancer patients from Northeastern Brazil

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, ...
EurekAlert!

Rare non-small cell lung cancer with brain metastases responds to amivantamab monotherapy

“This case challenges current paradigms, demonstrating that amivantamab monotherapy can effectively target rare EGFR mutations, achieve durable extracranial and CNS disease control, and potentially ...
EurekAlert!

Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report

Hematoxylin and eosin staining revealed poorly differentiated carcinoma with round cells and rhabdoid morphology (A, 100×). Positive expression of CK5/6 (B, 100×) and CK7 (C, 100×). Suggestive SMARCA4 ...
Cure Today

FDA Approves Hernexeos for Non-Squamous Non-Small Cell Lung Cancer

Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...